Summary by Moomoo AI
TransCode Therapeutics, Inc., a Delaware-based RNA oncology company, has successfully closed a public offering on January 22, 2024, raising approximately $7.25 million. The offering involved the sale of 5,942,623 shares of common stock or equivalent pre-funded warrants, along with common stock purchase warrants to buy an additional 11,885,246 shares, at a price of $1.22 per share or warrant. The common stock purchase warrants are exercisable at $1.22 per share and will expire three and a half years from the date of issuance. The pre-funded warrants, sold in place of common stock, are exercisable immediately at $0.01 per share and expire upon full exercise. Additionally, placement agent warrants were issued, allowing the purchase of up to 356,557 shares of common stock, exercisable at $1.525 per share. This offering...Show More